Improvement of voicing in patients with Parkinson’s disease by speech therapy

Speech therapy in PD patients, focusing on an increase of phonatory–respiratory effort, has adverse effects because it raises vocal pitch and laryngeal muscle tension. The authors’ approach, the Pitch Limiting Voice Treatment (PLVT), increases loudness but at the same time sets vocal pitch at a better level. In this study, the Lee Silverman Voice Treatment (“think loud, think shout”) and PLVT (“speak loud and low”) are compared. Both treatments produce the same increase in loudness, but PLVT limits an increase in vocal pitch and prevents a strained or pressed voicing.

[1]  Y Horii,et al.  Vocal shimmer in sustained phonation. , 1980, Journal of speech and hearing research.

[2]  P. Milenkovic,et al.  Least mean square measures of voice perturbation. , 1987, Journal of speech and hearing research.

[3]  J. P. Pabon,et al.  Objective acoustic voice-quality parameters in the computer phonetogram , 1991 .

[4]  Hermann Ackermann,et al.  Gender-Specific Vocal Dysfunctions in Parkinson's Disease: Electroglottographic and Acoustic Analyses , 1995, The Annals of otology, rhinology, and laryngology.

[5]  Voice therapy for neurologic disease , 1995 .

[6]  L. Ramig,et al.  Intensive voice treatment in Parkinson disease: laryngostroboscopic findings. , 1995, Journal of voice : official journal of the Voice Foundation.

[7]  S. Countryman,et al.  Intensive speech treatment for patients with Parkinson's disease , 1996, Neurology.

[8]  De klinische relevantie van het fonetogram: een onderzoek bij kinderen en leerkrachten , 1998 .

[9]  S. Countryman,et al.  Changes in vocal loudness following intensive voice treatment (LSVT®) in individuals with Parkinson's disease: A comparison with untreated patients and normal age‐matched controls , 2001, Movement disorders : official journal of the Movement Disorder Society.

[10]  L. Ramig,et al.  Current Perspectives on the Lee Silverman Voice Treatment (LSVT) for Individuals With Idiopathic Parkinson Disease , 2002 .

[11]  P T Fox,et al.  Hypophonia in Parkinson’s disease , 2003, Neurology.

[12]  C. Wessig,et al.  Creatine monohydrate in DM2/PROMM , 2003, Neurology.

[13]  Lippincott Williams Wilkins February 11 Highlights , 2003, Neurology.